MACPAC held a meeting December, 14-15, 2023 (link). The following relevant topics were discussed:

  • Data Update on Unwinding the Continuous Coverage Provisions
  • Potential Areas for Comment on CMS Proposed Rule on Medicare Advantage for CY2025 
  • Medicare-Medicaid Plan (MMP) Transition Monitoring: Interviews on Stakeholder Engagement 
  • Panel on the Medicare-Medicaid Plan Transitions and the Future of Integrated Care for Dually Eligible Individuals 

ADVI Angle

Key takeaways from the December meeting include:

  • Data Update on Unwinding the Continuous Coverage Provisions 
    • State unwinding outcomes vary widely. Overall enrollment has decreased by approximately 2.3 million individuals, including about 1.1 million children.
      • However, some states have reported increases in enrollment.
    • Commissioners discussed the use of disenrollment data, best methods to contact beneficiaries, and what other data sources they might use to inform future work.
  • Potential Areas for Comment on CMS Proposed Rule on Medicare Advantage for CY2025
    • Commissioners agreed with provisions in the proposed rule related to dual eligibles and discussed several areas for comment.
  • Medicare-Medicaid Plan (MMP) Transition Monitoring: Interviews on Stakeholder Engagement 
    • States have been engaging with MACPAC Staff on their Medicare-Medicaid plan transition monitoring. Commissioners discussed the importance of stakeholder engagement and continuous communication with states.
  • Panel on the Medicare-Medicaid Plan Transitions and the Future of Integrated Care for Dually Eligible Individuals 
    • Panelists shared challenges in transitioning from MMPs to D-SNPs, such as the lack of subject matter expertise in D-SNPs, as well as the opportunities that have come from this transition, including the incorporation of MMP best practices into D-SNP regulation. Key areas of interest for Commissioners included the authority of the Medicare-Medicaid Coordination Office, the human capital infrastructure in place across states, and the intersection between Medicare and Medicaid.

This is an abridged and delayed release. Full ADVI Analysis content is distributed in real time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.


Allison Schneider, MHA
Director

CEO insights

Real analysis from people who’ve been there

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption  

Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …

Marc Samuels, JD, MPH
December 30, 2025

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Cell and Gene

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …

Alicia Silver, MPP
November 21, 2025

Inflation Reduction Act Pharmaceuticals and Biotech

Why is Medicare Data Central to IRA Negotiations?

The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …

September 10, 2025

Rare Disease

The Unintended Consequences of Drug Pricing Policies on Orphan Drug Development

Rare diseases impact nearly 1 in 10 people in the US and are largely untreated, with 95 percent lacking FDA-approved …

Tyler Seville, MPA
June 23, 2025

State Policy

ADVI Analysis: HRSA 340B Covered Entity Audits

Analysis of HRSA 340B Covered Entity Audits Since the 340B Drug Pricing Program began in 1992, covered entities’ participation has …

March 10, 2025

ADVI Angle Vertical

Rare Disease State Policy

Prescription Drug Affordability Boards: Access Concerns and Implications for Rare Diseases and Conditions

In recent years, states have increasingly enacted Prescription Drug Affordability Boards (PDABs). While their stated purpose is to increase affordability, …

Allison Schneider, MHA
February 28, 2025

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.